Navigation Links
Study Shows New Option for Kids With Tough-to-Treat Leukemia
Date:4/12/2012

WEDNESDAY, April 11 (HealthDay News) -- Additional chemotherapy may a better option than bone marrow transplant for some children with acute lymphoblastic leukemia who don't respond to an initial intense regimen of chemotherapy called "induction therapy," a new study says.

Acute lymphoblastic leukemia, or ALL, is a cancer of the blood and bone marrow.

According to study co-author Dr. Ching-Hon Pui, failure to improve after induction therapy is rare, happening in just 2 percent to 3 percent of children with ALL. But when it does happen, these children's risk for a bad outcome rises considerably, so they often then become candidates for a bone marrow transplant.

However, the new study suggests that that option may not always be the only one.

"Some patients and their parents will be relieved to know that transplantation is not necessary for cure," said Pui, chair of the oncology department at St. Jude Children's Research Hospital in Memphis, Tenn. His team published their findings in the April 12 issue of the New England Journal of Medicine.

In the study, Pui and his colleagues tracked more than 1,000 children with ALL who did not go into remission after four to six weeks of induction therapy. The patients' cancer was diagnosed when they were between the ages of 1 to 5 years.

The overall survival rate for children with ALL who fail to go into remission following induction therapy was 32 percent. However, the rate was 72 percent in a subset of patients who had additional chemotherapy instead of a bone marrow transplant.

Pui's group noted that this type of patient had a form of ALL that begins in white blood cells destined to become B cells (B-lineage ALL). They accounted for about 25 percent of the more than 1,000 patients who did not go into remission following induction therapy.

Patients who fail induction therapy but may not require transplant, therefore, "are the patients who have B-cell precursor leukemia with no other adverse features," Pui said. "The remaining patients [who failed induction therapy] will be certain that transplantation is their best treatment for cure."

Another expert in leukemia care said the study offers valuable information.

"The study shows that even in these patients who have a poor response, there are a few subgroups that ultimately do well while there are other subgroups that do poorly and need bone marrow transplantation," said Dr. Arlene Redner, associate chief of oncology at Steven and Alexandra Cohen Children's Medical Center of New York in New Hyde Park, N.Y.

"This study will allow us to tailor our therapy in these patients and know that some of the patients who don't go into remission after the first month of therapy need bone marrow transplantation while others do not," she explained.

Still, the study did have its limits, Redner added. "The problems with the study are that the children were not all treated the same way and were treated over a long time period from 1985 and 2000. We now subdivide patients and treat them differently than during that time period."

More information

The U.S. National Cancer Institute has more about childhood acute lymphoblastic leukemia.

-- Robert Preidt

SOURCES: Ching-Hon Pui, M.D., chair, oncology department, St. Jude Children's Research Hospital, Memphis, Tenn.; Arlene Redner, associate chief, oncology, Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, N.Y.; St. Jude Children's Research Hospital, news release, April 11, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
2. Study finds significant skull differences between closely linked groups
3. Huntingtons Disease Linked to Reduced Cancer Risk in Study
4. Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study
5. Some Folks Just Cant Help Being Nice, Study Suggests
6. Codeine After Surgery Could Endanger Certain Kids: Study
7. Common Blood Pressure Drug Safe for Heart Failure: Study
8. Young Americans Need to Cut Calorie Intake: Study
9. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
10. Supporting LGB children may influence their long-term health, BU study finds
11. Climate Change Could Be Tough on Seniors Health: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Shows New Option for Kids With Tough-to-Treat Leukemia
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: